{"id":4755,"date":"2023-07-20T14:20:16","date_gmt":"2023-07-20T14:20:16","guid":{"rendered":"https:\/\/wapcpharm.org\/journal\/?p=4755"},"modified":"2023-07-31T14:25:11","modified_gmt":"2023-07-31T14:25:11","slug":"west-african-journal-of-pharmacy-2016-27-2-111-119","status":"publish","type":"post","link":"https:\/\/wapcpharm.org\/journal\/west-african-journal-of-pharmacy-2016-27-2-111-119\/","title":{"rendered":"West African Journal of Pharmacy (2016) 27 (2) 111-119"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Treatment outcomes of tuberculosis patients with diabetes mellitus <\/b>in a secondary health facility in Lagos Nigeria.<\/b><\/p>


<\/p>

Foluke Ayeni , Bolajoko Aina , Olubukola Oyetunde , Olusola Adejumo .<\/p>

1Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University of Lagos, <\/span>Idi Araba Campus, Lagos State, Nigeria.<\/span><\/p>


<\/p>

2Department of Community Health and Primary Health Care, Lagos State University Teaching Hospital, <\/span>Ikeja, Lagos, Nigeria<\/span><\/p>


<\/span><\/p>

Corresponding Author: Foluke Ayeni<\/p>

E-mail address: folukeayeni@live.com Phone : +234-8075614126<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

ABSTRACT<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Background:<\/b> The presence of diabetes mellitus (DM) has been shown by a growing body of evidence to be a\u00a0risk factor for tuberculosis (TB) and co-infected patients may show poor response to TB treatment as both\u00a0<\/span>diseases interact negatively.<\/span><\/p>

Objectives:<\/b> This study is aimed at determining associated factors and comparing the treatment outcomes of\u00a0TB patients living with and without DM in a secondary care TB treatment facility in Lagos state, Nigeria.<\/span><\/p>

Methods:<\/b> A retrospective review of patients records above 18 years’ enrolled between 1st January 2011 and\u00a031st December 2012 in a secondary care TB treatment facility in Lagos state was carried out.<\/span><\/p>

Results:<\/b> A total of 424 records of TB patients were reviewed, out of which 36 (8.5%) had DM. Mean age of\u00a0TBDM patients (50.0\u00b112.8) was higher than for TB-only patients (34.1\u00b113.8). Male: Female ratio of TBDM and\u00a0<\/span>TB only patients was comparable. All TBDM patients had pulmonary TB. Of these, proportion of smear\u00a0<\/span>negativity (72.2%) was significantly higher than TB only patients (34.9%, p <0.001). More TBDM patients\u00a0<\/span>(38.9%) compared to TB only patients (20.6%) had poor treatment outcomes (p = 0.012).<\/span><\/p>

Conclusion:<\/b> The prevalence of TBDM was substantial and it was associated with advanced age, smear negative\u00a0sputum result and poor treatment outcomes. Concurrent management of both diseases should be considered\u00a0<\/span>to improve treatment outcomes.<\/span><\/p>

KeyWords:<\/b> Tuberculosis, Diabetes Mellitus, Treatment outcomes, Lagos, Nigeria<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tDownload <\/span>\n\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Treatment outcomes of tuberculosis patients with diabetes mellitus in a secondary health facility in Lagos Nigeria. Foluke Ayeni , Bolajoko Aina , Olubukola Oyetunde , Olusola Adejumo . 1Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University of Lagos, Idi Araba Campus, Lagos State, Nigeria. 2Department of Community Health and Primary Health Care, Lagos State University […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[225],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/posts\/4755"}],"collection":[{"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/comments?post=4755"}],"version-history":[{"count":4,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/posts\/4755\/revisions"}],"predecessor-version":[{"id":4761,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/posts\/4755\/revisions\/4761"}],"wp:attachment":[{"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/media?parent=4755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/categories?post=4755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/tags?post=4755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}